

# A clinical trial to investigate if proton beam therapy with chemotherapy given before surgery for patients with oesophageal cancer that has spread to the surrounding tissues, significantly reduces the severe side effects to the heart and lungs and allows immunotherapy to be started sooner after surgery when compared with standard radiotherapy and chemotherapy before surgery, and whether this delivers value to the NHS and patients

Submission date	Recruitment status	<input checked="" type="checkbox"/> Prospectively registered
27/12/2023	Recruiting	<input checked="" type="checkbox"/> Protocol
Registration date	Overall study status	<input type="checkbox"/> Statistical analysis plan
15/02/2024	Ongoing	<input type="checkbox"/> Results
Last Edited	Condition category	<input type="checkbox"/> Individual participant data
06/02/2026	Cancer	<input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Although the optimal treatment strategy in oesophageal (food pipe) cancer has been the subject of research for several decades, overall outcomes are very poor, with a 5-year survival of 15%. In the UK there are 9100 new cases of oesophago-gastric cancer diagnosed and approximately 7925 deaths every year (Cancer Research UK Oct 2019). Oesophageal cancer is a strategic priority for CRUK and a serious health problem world-wide. Pre-surgery treatment consists of chemotherapy with/without immunotherapy or chemoradiation, but the optimal treatment is unknown. Over 60% of patients experience severe side-effects from their treatment and this impacts their outcomes. Proton beam therapy is a new radiotherapy treatment; there are currently only 2 centres in England with Proton beam therapy machines. Proton beam therapy may help to reduce side-effects and is an important avenue of research. This trial has been funded by CRUK.

This study aims to investigate if Proton beam therapy and chemotherapy given before surgery for oesophageal cancer significantly reduces the risk of severe toxicity and prevents delay of post-operative immunotherapy when compared with standard photon radiotherapy.

## Who can participate?

Patients over 16 years old with resectable oesophageal cancer.

## What does the study involve?

Patients will be randomised 1:1 into the experimental arm (Proton beam therapy, chemotherapy +/- immunotherapy + surgery) and control arm (photon radiotherapy, chemotherapy +/- immunotherapy + surgery). After surgery patients can be treated with standard of care systemic anti-cancer therapy which would be chemotherapy and/or immunotherapy. Patients suitable for immunotherapy will receive up to 12 months of treatment after surgery as per standard of care. This UK trial will recruit patients from 15 NHS sites; all patients randomised to receive Proton beam therapy will be treated at either UCLH/Christie. Patients will receive treatment for 5-11 weeks before surgery (the duration of chemotherapy depends on the most suitable chemotherapy for their cancer type), and for up to 1 year after surgery. Patients will be followed up at NHS sites for up to 1 year, and then survival data will be collected from NHS data registries for a further 2 years.

## What are the possible benefits and risks of participating?

The potential risks and burden will only be applicable to patients randomised to the experimental arm to receive Proton-beam therapy over a period of 3 weeks. Patients on the control arm will be treated as per standard of care. There is a risk of financial burden on patients allocated proton beam therapy who will need to travel to one of the two proton beam centres for their specialised radiotherapy treatment. Patients will be required to organise the travel themselves with the help of their 'key worker' from the relevant Proton beam therapy centre. Patients may also be required to stay away from home for 3 weeks if they live far away from one of the 2 proton beam centres, and free accommodation is provided for patients and a carer at the proton beam centres. As with any radiotherapy there may be some long-term side effects. The study doctor or nurse will go through these with trial patients and this information is included in the patient information sheet. The adverse events from Proton beam therapy are considered to be low risk, as the concept of Proton beam therapy is to negate the effects of radiation to the healthy tissues surrounding the tumour, mainly healthy lung and heart tissue. The treating team will be monitoring patients for any side effects during and after treatment and will be taking care of any long-term adverse events for up to a year after surgery. There may be no direct benefit to research participants and this is explained in the patient information sheet. Research participants enrolled in the trial will have a 50% chance of receiving PBT for their oesophageal cancer, which is not currently available off trial, which may or may not improve their survival and quality of life from potentially fewer side effects than standard photon based radiotherapy. With 2 proton beam centres now in England, patients will no longer have to travel overseas for their PBT treatment. Patients in this study will have access to this new treatment, possibly increasing the chances of a long-term cure. Proton beam therapy may make immunotherapy easier to tolerate and possibly more effective. However, none of this is proven and there is no guarantee that individual patients will benefit directly from taking part in this study. We hope the information we gain from the study will benefit people who develop oesophageal cancer in the future. If the trial is a success and shows PBT treatment is better than photon beam radiotherapy then the standard of care may change in future.

## Where is the study run from?

University College London (UK)

## When is the study starting and how long is it expected to run for?

January 2024 to June 2032

Who is funding the study?  
Cancer Research UK  
The Taylor Family Foundation (UK)

Who is the main contact?  
ctc.protieus@ucl.ac.uk

<https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-proton-beam-radiotherapy-for-oesophageal-cancer-and-gastroesophageal-junction>

## Contact information

### Type(s)

Scientific

### Contact name

Dr Natasha Hava

### Contact details

Cancer Research UK & UCL Cancer Trials Centre, 90 Tottenham Court Road  
London  
United Kingdom  
W1T 4TJ  
+44 207 679 9608  
ctc.protieus@ucl.ac.uk

### Type(s)

Principal investigator

### Contact name

Prof Maria Hawkins

### ORCID ID

<https://orcid.org/0000-0002-6669-0628>

### Contact details

Department of Medical Physics & Biomedical Engineering Faculty of Engineering Science  
University College London  
London  
United Kingdom  
WC1E 6BT  
+44 20 7679 0262 Ext: 30262  
m.hawkins@ucl.ac.uk

## Additional identifiers

**Clinical Trials Information System (CTIS)**  
Nil known

**Integrated Research Application System (IRAS)**

329646

**ClinicalTrials.gov (NCT)**

Nil known

**Central Portfolio Management System (CPMS)**

58475

## Study information

### Scientific Title

A randomised Phase II trial comparing proton versus photon-based neoadjuvant chemoradiation, followed by standard therapy, in oesophageal cancer

### Acronym

PROTIEUS

### Study objectives

Proton beam therapy given concurrently with chemotherapy before surgery significantly reduces the risk of severe toxicity and prevents delay of post-operative immunotherapy when compared with standard photon radiotherapy for oesophageal cancer.

### Ethics approval required

Ethics approval required

### Ethics approval(s)

approved 23/01/2024, The London - Camden & Kings Cross Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 207 104 8086; CamdenandKingsCross.REC@hra.nhs.uk), ref: 23/LO/0964

### Study design

Interventional randomized controlled trial

### Primary study design

Interventional

### Study type(s)

Treatment

### Health condition(s) or problem(s) studied

Oesophageal cancer

### Interventions

Current interventions as of 06/02/2026:

Eligible patients will be allocated by a computer devised programme into one of the treatment groups: A) a group receiving proton beam radiotherapy (PBT) or B) a group receiving standard of care treatment photon radiotherapy. All patients will receive 3 weeks of daily radiation and 5-7 courses of chemotherapy once weekly/fortnightly, with/without immunotherapy, followed by surgery. Patients in PBT group will travel to one of the proton beam centres either in Manchester or London. After chemoradiotherapy, all patients will have

surgery and they will receive up to 4 fortnightly cycles of chemotherapy and/or immunotherapy for up to 1 year after their surgery, which starts approximately 4 to 12 weeks after surgery. The frequency when the patient should receive immunotherapy, for example, once every 2 or 4 weeks, will depend on the local hospital's policy.

After finishing surgery, all patients will be seen at clinic (follow-up visits) at the first month after the surgery, then every 3 months for up to a 1 year. Further follow-up data will be collected remotely via a data collection service called NHS Digital (NHS England data registries).

There is also a translational research component where extra blood will be taken from patients, and tissue samples from the diagnostic biopsy and surgical specimen will be collected for use in research.

#### Previous interventions:

Eligible patients will be allocated by a computer devised programme into one of the treatment groups: A) a group receiving proton beam radiotherapy (PBT) or B) a group receiving standard of care treatment photon radiotherapy. All patients will receive 3 weeks of daily radiation and 5 courses of chemotherapy once weekly, followed by surgery. Patients in PBT group will travel to one of the proton beam centres either in Manchester or London. After chemoradiotherapy, all patients will have surgery and if they have a small amount of remaining cancer cells (residual disease) after surgery, they will receive immunotherapy for up to 1 year after their surgery, approximately 4 to 12 weeks after surgery. The frequency when the patient should receive immunotherapy, for example, once every 2 or 4 weeks, will depend on the local hospital's policy.

After finishing surgery, all patients will be seen at clinic (follow-up visits) at the first month after the surgery, then every 3 months for up to a 1 year. Further follow-up data will be collected remotely via a data collection service called NHS Digital (NHS England data registries).

There is also a translational research component where extra blood and tissue samples will be taken from patients.

#### Intervention Type

Procedure/Surgery

#### Primary outcome(s)

Frequency and percentage of patients that experience severe post operative complications prior to or at the follow-up assessment 3 months after surgery measured using adverse event data entered on the database by sites which is graded using both the CTCAE and the Clavien Dindo Scale

#### Key secondary outcome(s)

Preliminary data on longer term efficacy outcomes following 1 year of adjuvant immunotherapy for patients that do not achieve pathologic complete response at surgery measured using survival data and the number and percentages of different types of disease recurrences

#### Completion date

01/06/2032

## Eligibility

#### Key inclusion criteria

1. 16 years of age or older
2. Histologically confirmed diagnosis of oesophageal adenocarcinoma (OAC) or squamous cell carcinoma (OSCC)

3. Tumour of the thoracic oesophagus or gastroesophageal junction with distal maximum extension no more than 3 cm beyond the gastroesophageal junction
4. cT stage  $\geq 2$  and/or cN stage  $\geq 0-2$  defined by AJCC 8th edition
5. ECOG performance status 0-1
6. Suitable for and fit to receive curative neoadjuvant Chemoradiotherapy followed by surgery by an Upper GI MDT
7. Suitable for and fit to receive adjuvant Immunotherapy according to local guidelines
8. Adequate cardiovascular and respiratory function for surgery in the opinion of the surgical team within 4 weeks prior to randomisation
9. Willing and able to give written informed consent and able to comply with treatment and follow up schedule
10. Willing and able to undergo treatment at a PBT centre (i.e. UCLH or The Christie) if randomised to Proton Arm

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Mixed

**Lower age limit**

16 years

**Upper age limit**

100 years

**Sex**

All

**Total final enrolment**

0

**Key exclusion criteria**

1. Metastatic disease or extensive nodal disease (N3).
2. Patients who have had previous treatment for invasive oesophageal carcinoma or gastroesophageal junction carcinoma (including Photo Dynamic Therapy or laser therapy for high grade dysplasia/carcinoma in-situ).
3. Patients with  $> 3$ cm mucosal extension of tumour into the stomach beyond the GOJ or where the superior extent is in the cervical oesophagus
4. Tumour length based on position:
  - 4.1. Length of primary tumour  $> 10$  cm in thorax, or
  - 4.2.  $> 12$  cm in the gastroesophageal junction or lower third of the oesophagus, or
  - 4.3. Total length of disease (primary tumour and involved lymph nodes) length  $> 14$  cm for lower third tumours.
5. Patients with unstable angina, uncontrolled hypertension, cardiac failure or arrhythmia and other clinically significant cardiac disease.
6. Patients with an oesophageal stent (patients requiring a PEG/RIG/feeding jejunostomy for nutritional purposes ARE eligible).

7. No relevant co-morbidities, including Usual Interstitial Pneumonia (UIP) pulmonary fibrosis and connective tissue disorders.
8. History of other malignancy likely to interfere with the protocol treatment (e.g. patients with previously treated malignancy who have been disease-free for < 1 year, or patients with active malignancy undergoing treatment). Exceptions:
  - 8.1. Subjects who have been successfully treated and disease-free for > 3 years,
  - 8.2. A history of treated non-melanoma skin cancer,
  - 8.3. Successfully treated in situ carcinoma,
  - 8.4. CLL in stable remission, or indolent prostate cancer requiring no or only anti-hormonal therapy.
9. Any other situation, which in the opinion of the local PI, makes the patient unsuitable for this trial.
10. Women who are pregnant or breastfeeding.
11. Patients unable to adhere to the contraception guidance in the protocol.

**Date of first enrolment**

11/06/2024

**Date of final enrolment**

01/02/2028

## Locations

**Countries of recruitment**

United Kingdom

England

Wales

**Study participating centre**

**University College London Hospitals NHS Foundation Trust**

250 Euston Road

London

England

NW1 2PG

**Study participating centre**

**The Clatterbridge Cancer Centre NHS Foundation Trust**

Clatterbridge Hospital

Clatterbridge Road

Bebington

Wirral

England

CH63 4JY

**Study participating centre**

**Guys and St Thomas' NHS Foundation Trust**  
249 Westminster Bridge Road  
London  
England  
SE1 7EH

**Study participating centre**

**Norfolk and Norwich University Hospitals NHS Foundation Trust**  
Colney Lane  
Colney  
Norwich  
England  
NR4 7UY

**Study participating centre**

**Royal Free London NHS Foundation Trust**  
Royal Free Hospital  
Pond Street  
London  
England  
NW3 2QG

**Study participating centre**

**Swansea Bay University Local Health Board**  
Tonna Hospital  
Tonna Uchaf  
Tonna  
Neath  
Wales  
SA11 3LX

**Study participating centre**

**Leeds Teaching Hospitals NHS Trust**  
St. James's University Hospital  
Beckett Street  
Leeds  
England  
LS9 7TF

**Study participating centre**

**The Christie NHS Foundation Trust**  
550 Wilmslow Road  
Withington  
Manchester  
England  
M20 4BX

**Study participating centre**

**Hull University Teaching Hospitals NHS Trust**  
Hull Royal Infirmary  
Anlaby Road  
Hull  
England  
HU3 2JZ

**Study participating centre**

**Royal Devon University Healthcare NHS Foundation Trust**  
Royal Devon University NHS Ft  
Barrack Road  
Exeter  
England  
EX2 5DW

**Study participating centre**

**Cambridge University Hospitals NHS Foundation Trust**  
Cambridge Biomedical Campus  
Hills Road  
Cambridge  
England  
CB2 0QQ

**Study participating centre**

**Oxford University Hospitals NHS Foundation Trust**  
John Radcliffe Hospital  
Headley Way  
Headington  
Oxford  
England  
OX3 9DU

**Study participating centre**

**University Hospitals Plymouth NHS Trust**  
Derriford Hospital  
Derriford Road  
Derriford  
Plymouth  
England  
PL6 8DH

**Study participating centre**

**Velindre NHS Trust**  
Unit 2  
Charnwood Court  
Heol Billingsley  
Cardiff  
Wales  
CF15 7QZ

## Sponsor information

**Organisation**

University College London

**ROR**

<https://ror.org/02jx3x895>

## Funder(s)

**Funder type**

Charity

**Funder Name**

Cancer Research UK

**Alternative Name(s)**

CR\_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

**Funding Body Type**

Private sector organisation

**Funding Body Subtype**

Other non-profit organizations

**Location**  
United Kingdom

**Funder Name**  
The Taylor Family Foundation

## Results and Publications

### Individual participant data (IPD) sharing plan

#### IPD sharing plan summary

Data sharing statement to be made available at a later date

#### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Participant information sheet</a>	version 3.0	08/01/2026	06/02/2026	No	Yes
<a href="#">Participant information sheet</a>	version 3.0	08/01/2026	06/02/2026	No	Yes
<a href="#">Protocol file</a>	version 5.0		06/02/2026	No	No